Gene Detail

Gene Symbol KDR
Synonyms CD309 | FLK1 | VEGFR | VEGFR2
Gene Description KDR (VEGFR2), vascular endothelial growth factor receptor 2, is an endothelial cell surface receptor tyrosine kinase and member of the vascular endothelial growth factor family of proteins that plays a role in angiogenesis and cell proliferation through activation of RAF-MEK-MAP and PI3K-AKT pathways (PMID: 25568876, PMID: 29093528, PMID: 26578684). KDR amplification and overexpression have been reported in a variety of tumor types (PMID: 21382095, PMID: 27218826, PMID: 25231439, PMID: 20606037) and somatic mutations have been reported in sarcomas and head and neck squamous cell carcinomas (PMID: 22314185, PMID: 11801954).
Entrez Id 3791
Chromosome 4
Map Location 4q12
Canonical Transcript NM_002253

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Variant Impact Protein Effect Variant Description Associated with drug Resistance
G800D missense gain of function - predicted KDR (VEGFR2) G800D lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). G800D has not been biochemically characterized, however, promotes tumor formation in xenograft models (PMID: 29588308), and therefore, is predicted to confer a gain of function to the Kdr (Vegfr2) protein.
D1174Y missense unknown KDR (VEGFR2) D1174Y lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). D1174Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
P1147S missense unknown KDR (VEGFR2) P1147S lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). Y822C has been identified in the scientific literature (PMID: 11807987), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
Q472H missense gain of function KDR (VEGFR2) Q472H does not lie within any known functional domains of the Kdr (Vegfr2) protein (UniProt.org). Q472H confers a gain of function to the Kdr (Vegfr2) protein, resulting in increased phosphorylation of Kdr (Vegfr2) in cell culture, increased serum VEGF levels, and increased microvessel density in tumor samples (PMID: 21712447, PMID: 26631613).
V655M missense unknown KDR (VEGFR2) V655M lies within the Ig-like C2-type domain 6 of the Kdr (Vegfr2) protein (UniProt.org). V655M has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
S1221N missense unknown KDR (VEGFR2) S1221N lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). S1221N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
D1254N missense unknown KDR (VEGFR2) D1254N lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). D1254N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
D832Y missense unknown KDR (VEGFR2) D832Y lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). D832Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
R1022Q missense gain of function - predicted KDR (VEGFR2) R1022Q lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R1022Q has not been biochemically characterized, however, promotes tumor formation in xenograft models (PMID: 29588308), and therefore, is predicted to confer a gain of function to the Kdr (Vegfr2) protein.
mutant unknown unknown KDR mutant indicates an unspecified mutation in the KDR (VEGFR2) gene.
W1096R missense unknown KDR (VEGFR2) W1096R lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). W1096R has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Nov 2018).
wild-type none no effect Wild-type KDR (VEGFR2) indicates that no mutation has been detected within the KDR (VEGFR2) gene.
R275* nonsense loss of function - predicted KDR (VEGFR2) R275* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 275 of 1356 (UniProt.org). Due to a loss of multiple functional domains, including the protein kinase domain (UniProt.org), R275* is predicted to lead to a loss of Kdr protein function.
P1210L missense unknown KDR (VEGFR2) P1210L lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). P1210L has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
act mut unknown gain of function KDR act mut indicates that this variant results in a gain of function in the Kdr (Vegfr2) protein. However, the specific amino acid change has not been identified.
G539R missense gain of function - predicted KDR (VEGFR2) G539R lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). G539R is associated with increased expression of Kdr (Vegfr2) and increased ligand-dependent Erk phosphorylation in cell culture (JCO Precision Oncology 2017:1, 1-13), and therefore, is predicted to lead to a gain of Kdr (Vegfr2) protein function.
S984T missense unknown KDR (VEGFR2) S984T lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). S984T has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
H1026N missense unknown KDR (VEGFR2) H1026N lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). H1026N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
F921C missense unknown KDR (VEGFR2) F921C lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). F921C has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
L1140M missense unknown KDR (VEGFR2) L1140M lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). L1140M has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G1308* nonsense unknown KDR (VEGFR2) G1308* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1308 of 1356 (UniProt.org). G1308* has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
T771R missense unknown KDR (VEGFR2) T771R lies within the helical domain of the Kdr (Vegfr2) protein (UniProt.org). T771R has been identified in the scientific literature (PMID: 19723655), but has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
P1210S missense unknown KDR (VEGFR2) P1210S lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). P1210S has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G1015D missense unknown KDR (VEGFR2) G1015D lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G1015D has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
W1096L missense unknown KDR (VEGFR2) W1096L lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). W1096L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G1145R missense unknown KDR (VEGFR2) G1145R lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G1145R has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
R1124K missense unknown KDR (VEGFR2) R1124K lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R1124K has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
S35I missense unknown KDR (VEGFR2) S35I lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). S35I has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
V1041M missense unknown KDR (VEGFR2) V1041M lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). V1041M has been identified in sequencing studies (PMID: 18772396), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
L1049W missense unknown KDR (VEGFR2) L1049W lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). L1049W has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
E469K missense unknown KDR (VEGFR2) E469K lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). E469K has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
K353N missense unknown KDR (VEGFR2) K353N lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). K353N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G843D missense gain of function - predicted KDR (VEGFR2) G843D lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G843D has not been biochemically characterized, however, promotes tumor formation in xenograft models (PMID: 29588308), and therefore, is predicted to confer a gain of function to the Kdr (Vegfr2) protein.
S1100F missense unknown KDR (VEGFR2) S1100F lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). The functional effect of S1100F is conflicting, as S1100F results in decreased ligand-induced phosphorylation of Krd (Vegfr2) and Mapk in cell culture (PMID: 28743916), but induces tumor growth in cell line xenografted mice above wild-type (PMID: 29588308).
C737Y missense unknown KDR (VEGFR2) C737Y lies within the Ig-like C2-type domain 7 of the Kdr (Vegfr2) protein (UniProt.org). C737Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
V476L missense unknown KDR (VEGFR2) V476L lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). V476L has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
R1032* nonsense unknown KDR (VEGFR2) R1032* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1032 of 1356 (UniProt.org). R1032* has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
R1150I missense unknown KDR (VEGFR2) R1150I lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R1150I has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G1308R missense unknown KDR (VEGFR2) G1308R lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). G1308R has been identified in sequencing studies (PMID: 25056374), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G846D missense unknown KDR (VEGFR2) G846D lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G846D has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
A1065T missense gain of function - predicted KDR (VEGFR2) A1065T lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). A1065T is predicted to confer a gain of function to the Kdr (Vegfr2) protein, as demonstrated by constitutive tyrosine autophosphorylation (PMID: 19723655).
Q37H missense unknown KDR (VEGFR2) Q37H lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). Q37H has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
A331G missense unknown KDR (VEGFR2) A331G lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). A331G has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
D717V missense unknown KDR (VEGFR2) D717V lies within the Ig-like C2-type domain 7 of the Kdr (Vegfr2) protein (PMID: 19723655). The functional effect of D717V is conflicting, as D717V confers a gain of function to the Kdr (Vegfr2) protein, resulting in constitutive tyrosine autophosphorylation (PMID: 19723655), but does not induce tumor growth in cell line xenografted mice above wild-type (PMID: 29588308).
G509E missense unknown KDR (VEGFR2) G509E lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). G509E has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
M1016K missense unknown KDR (VEGFR2) M1016K lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). M1016K has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
T1152M missense unknown KDR (VEGFR2) T1152M lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). T1152M has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
R275L missense unknown KDR (VEGFR2) R275L lies within the Ig-like C2-type domain 3 of the Kdr (Vegfr2) protein (UniProt.org). R275L has been identified in sequencing studies (PMID: 16959974), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
over exp none no effect KDR (VEGFR2) over exp indicates an over expression of the Kdr (Vegfr2) protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
R1032Q missense unknown KDR (VEGFR2) R1032Q lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). The functional effect of R1032Q is conflicting, as R1032Q results in decreased ligand-induced phosphorylation of Kdr (Vegfr2) and Mapk in cell culture (PMID: 28743916), but induces tumor growth in cell line xenografted mice above wild-type (PMID: 29588308).
Y365H missense unknown KDR (VEGFR2) Y365H lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). Y365H has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
D985N missense unknown KDR (VEGFR2) D985N lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). D985N has been identified in sequencing studies (PMID: 28822769), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
G800R missense gain of function - predicted KDR (VEGFR2) G800R lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). G800R has not been biochemically characterized, however, promotes tumor formation in xenograft models (PMID: 29588308), and therefore, is predicted to confer a gain of function to the Kdr (Vegfr2) protein.
R1118* nonsense unknown KDR (VEGFR2) R1118* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1118 of 1356 (UniProt.org). R1118* has been identified in sequencing studies (PMID: 28481359), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Aug 2018).
G394R missense unknown KDR (VEGFR2) G394R lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). G394R has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
R164I missense unknown KDR (VEGFR2) R164I lies within the Ig-like C2-type domain 2 of the Kdr (Vegfr2) protein (UniProt.org). R164I has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
T139N missense unknown KDR (VEGFR2) T139N lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). T139N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
D39Y missense unknown KDR (VEGFR2) D39Y lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). D39Y has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
S1231N missense unknown KDR (VEGFR2) S1231N lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). S1231N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G873R missense unknown KDR (VEGFR2) G873R lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G873R has been identified in sequencing studies (PMID: 16959974), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
S1021L missense unknown KDR (VEGFR2) S1021L lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). S1021L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
amp none no effect KDR (VEGFR2) amplification indicates an increased number of copies of the KDR (VEGFR2) gene. However, the mechanism causing the increase is unspecified.
V297I missense unknown KDR (VEGFR2) V297I lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). The functional effect of V297I is conflicting, as V297I had no effect on Kdr (Vegfr2) phosphorylation levels in cell culture (PMID: 21712447), however in another study, V297I was suggested to have reduced ligand binding to Vegf in cell culture (PMID: 17707181).
E1325* nonsense unknown KDR (VEGFR2) E1325* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1325 of 1356 (UniProt.org). E1325* has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
R944Q missense unknown KDR (VEGFR2) R944Q lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R944Q has been identified in sequencing studies (PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
R73M missense unknown KDR (VEGFR2) R73M lies within the Ig-like C2-type domain 1 of the Kdr (Vegfr2) protein (UniProt.org). R73M has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
A352V missense unknown KDR (VEGFR2) A352V lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). A352V has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
V159M missense unknown KDR (VEGFR2) V159M lies within the Ig-like C2-type domain 2 of the Kdr (Vegfr2) protein (UniProt.org). V159M has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
A973S missense unknown KDR (VEGFR2) A973S lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). A973S has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
R961W missense unknown KDR (VEGFR2) R961W lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R961W has been identified in the scientific literature (PMID: 27004155), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
I1077L missense unknown KDR (VEGFR2) I1077L lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). I1077L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G1145E missense unknown KDR (VEGFR2) G1145E lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G1145E has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
L840F missense unknown KDR (VEGFR2) L840F lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). The functional effect of L840F is conflicting, as it results in a loss of Kdr (Vegfr2) kinase activity in culture, but promotes tumor development in xenograft models, and is associated with resistance to Kdr (VEGFR2) inhibitors (PMID: 29588308). Y
P421L missense unknown KDR (VEGFR2) P421L lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). P421L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
R347H missense unknown KDR (VEGFR2) R347H lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). R347H has been identified in sequencing studies (PMID: 23263491), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
A467T missense unknown KDR (VEGFR2) A467T lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). A467T has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
A248G missense unknown KDR (VEGFR2) A248G lies within the Ig-like C2-type domain 3 of the Kdr (Vegfr2) protein (UniProt.org). A248G has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
T343M missense unknown KDR (VEGFR2) T343M lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). T343M has been identified in sequencing studies (PMID: 24145436), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
S338Y missense unknown KDR (VEGFR2) S338Y lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). S338Y has been identified in sequencing studies (PMID: 22810696), but has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
G394E missense unknown KDR (VEGFR2) G394E lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). G394E has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
P1355S missense unknown KDR P1355S does not lie within any known functional domains of the Kdr protein (UniProt.org). P1355S has not been characterized in the scientific literature and therefore, its effect on Kdr protein function is unknown (PubMed, Aug 2018).
K366T missense unknown KDR (VEGFR2) K366T lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). K366T has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
S925F missense gain of function - predicted KDR (VEGFR2) S925F lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). S925F has not been biochemically characterized, however, promotes tumor formation in xenograft models (PMID: 29588308), and therefore, is predicted to confer a gain of function to the Kdr (Vegfr2) protein.
F1115C missense unknown KDR (VEGFR2) F1115C lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). F1115C has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
C482R missense unknown KDR (VEGFR2) C482R lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). C482R demonstrated phosphorylation similar to wild-type Kdr (Vegfr2) in culture (PMID: 21712447), however, in another study C428R demonstrated ligand-independent constitutive activation as indicated by increased KDR (VEGFR2) phosphorylation and enhanced dimerization (PMID: 27052508) and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Nov 2018).
Y822C missense unknown KDR (VEGFR2) Y822C lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). Y822C has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
positive unknown unknown KDR (VEGFR2) positive indicates the presence of the KDR gene, mRNA, and/or protein.
S26G missense unknown KDR (VEGFR2) S26G lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). S26G has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
D998N missense unknown KDR (VEGFR2) D998N lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). D998N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
P1355del deletion unknown KDR (VEGFR2) P1355del results in the deletion of an amino acid in the cytoplasmic domain of the Kdr (Vegfr2) protein at amino acid 1355 (UniProt.org). P1355del has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
D639Y missense unknown KDR (VEGFR2) D639Y lies within the Ig-like C2-type domain 6 of the Kdr (Vegfr2) protein (UniProt.org). D639Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
E1114* nonsense unknown KDR (VEGFR2) E1114* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1114 of 1356 (UniProt.org). E1114* has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
R962H missense unknown KDR (VEGFR2) R962H lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R962H has been identified in sequencing studies (PMID: 27077911), but has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
E759V missense unknown KDR (VEGFR2) E759V lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). E759V has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jan 2018).
L1184F missense unknown KDR (VEGFR2) L1184F lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). L1184F has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
L462V missense unknown KDR (VEGFR2) L462V lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) (UniProt.org). L462V has been identified in sequencing studies (PMID: 27997549), but not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Mar 2018).
Molecular Profile Protein Effect Treatment Approaches
KDR G800D gain of function - predicted
KDR D1174Y unknown
KDR P1147S unknown
EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T
KDR Q472H gain of function VEGFR Inhibitor (Pan) VEGFR2 Inhibitor
KDR V655M unknown
KDR S1221N unknown
KDR D1254N unknown
KDR D832Y unknown
KDR R1022Q gain of function - predicted
KDR mutant unknown
KDR W1096R unknown
KDR wild-type no effect
KDR R275* loss of function - predicted
KDR P1210L unknown
KDR act mut gain of function VEGFR Inhibitor (Pan) VEGFR2 Inhibitor
KDR G539R gain of function - predicted
KDR S984T unknown
KDR H1026N unknown
KDR F921C unknown
KDR L1140M unknown
KDR G1308* unknown
KDR T771R unknown
KDR P1210S unknown
KDR G1015D unknown
KDR W1096L unknown
KDR G1145R unknown
KDR R1124K unknown
KDR S35I unknown
KDR V1041M unknown
KDR L1049W unknown
KDR E469K unknown
KDR K353N unknown
KDR G843D gain of function - predicted
KDR S1100F unknown
KDR C737Y unknown
KDR V476L unknown
KDR R1032* unknown
KDR R1150I unknown
KDR G1308R unknown
KDR G846D unknown
KDR A1065T gain of function - predicted VEGFR Inhibitor (Pan) VEGFR2 Inhibitor
KDR Q37H unknown
KDR A331G unknown
KDR D717V unknown VEGFR Inhibitor (Pan) VEGFR2 Inhibitor
KDR G509E unknown
KDR M1016K unknown
KDR T1152M unknown
KDR R275L unknown
KDR over exp no effect
KDR R1032Q unknown
KDR Y365H unknown
KDR D985N unknown
KDR G800R gain of function - predicted
KDR R1118* unknown
KDR G394R unknown
KDR R164I unknown
KDR T139N unknown
KDR D39Y unknown
KDR S1231N unknown
KDR G873R unknown
KDR S1021L unknown
ROS1 fusion KDR amp KIT amp PDGFRA amp
KDR amp no effect
KDR V297I unknown
KDR E1325* unknown
KDR R944Q unknown
KDR R73M unknown
KDR A352V unknown
KDR V159M unknown
KDR A973S unknown
KDR R961W unknown
APC mutant KRAS mutant KDR R961W
KDR I1077L unknown
KDR G1145E unknown
KDR L840F unknown
KDR P421L unknown
KDR R347H unknown
KDR A467T unknown
KDR A248G unknown
KDR T343M unknown
KDR S338Y unknown
KDR G394E unknown
KDR P1355S unknown
KDR K366T unknown
KDR S925F gain of function - predicted
KDR F1115C unknown
KDR C482R unknown
KDR Y822C unknown
KDR pos RET C634W
KDR positive unknown
KDR S26G unknown
KDR D998N unknown
KDR P1355del unknown
KDR D639Y unknown
KDR E1114* unknown
KDR R962H unknown
KDR E759V unknown
KDR L1184F unknown
KDR L462V unknown
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T olfactory neuroblastoma sensitive Cetuximab + Sunitinib Clinical Study Actionable In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458). 27149458
KDR Q472H melanoma sensitive unspecified VEGFR2 antibody Preclinical Actionable In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613). 26631613
KDR wild-type Advanced Solid Tumor predicted - sensitive Pz-1 Preclinical Actionable In a preclinical study, Pz-1 inhibited Kdr2 phosphorylation in transformed cells expressing KDR wild-type (PMID: 26126987). 26126987
KDR wild-type Advanced Solid Tumor predicted - sensitive Ramucirumab Phase I Actionable In a Phase I trial, Cyramza (ramucirumab), an inhibitor of KDR (VEGFR2), demonstrated safety and efficacy (partial response or stable disease) in patients with advanced solid tumors (PMID: 20048182). 20048182
KDR wild-type pancreatic cancer sensitive VEGFR2-169 + Gemcitabine Phase I Actionable In a Phase I trial, VEGFR2-169, in combination with Gemzar (gemcitabine), achieved a disease control rate of 67% (12/18) and an improved overall survival time to 8.7 months in pancreatic cancer patients expressing the HLA-A*2402 version of the KDR (VEGFR2) wild-type allele (PMID: 19930156). 19930156
KDR act mut Advanced Solid Tumor sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655). 19723655
KDR act mut Advanced Solid Tumor sensitive Sunitinib Preclinical Actionable In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655). 19723655
KDR act mut bladder urothelial carcinoma predicted - sensitive Sunitinib Phase II Actionable In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593). 20142593
KDR act mut Advanced Solid Tumor predicted - sensitive Lucitanib Phase I Actionable In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991). 25193991
KDR A1065T Advanced Solid Tumor sensitive Sunitinib Preclinical Actionable In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655). 19723655
KDR D717V Advanced Solid Tumor sensitive Sunitinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing KDR D717V were sensitive to Sutent (sunitinib) in culture (PMID: 19723655). 19723655
KDR over exp breast cancer predicted - resistant Sunitinib Preclinical Actionable In a preclinical study, upregulation of Kdr (Vegfr2) was identified in tumors acquired resistance to Sutent (sunitinib) in allograft models of breast cancer (PMID: 28011623). 28011623
ROS1 fusion KDR amp KIT amp PDGFRA amp non-small cell lung carcinoma predicted - resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358). 29636358
KDR amp non-small cell lung carcinoma no benefit Vandetanib Phase III Actionable In a retrospective analysis of a Phase III trial, treatment with Caprelsa (vandetanib) did not correlate with an improved PFS, OS, or objective response rate in non-small cell lung carcinoma patients harboring a KDR amplification nor did it inhibit cell proliferation of the KDR amplified archived tumor cells in culture (PMID: 26578684). 26578684
APC mutant KRAS mutant KDR R961W colorectal cancer sensitive Regorafenib Clinical Study Actionable In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155). 27004155
KDR pos RET C634W thyroid medullary carcinoma predicted - sensitive Motesanib Preclinical - Cell line xenograft Actionable In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803). 21422803
KDR positive pancreatic cancer sensitive TAS-115 Preclinical Actionable In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932). 24140932
KDR positive melanoma predicted - sensitive Anti-VEGFR2 CAR CD8 lymphocytes Preclinical Actionable In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494). 23633494
KDR positive Advanced Solid Tumor predicted - sensitive Anti-VEGFR2 CAR CD8 lymphocytes Preclinical Actionable In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347). 20978347
KDR positive Advanced Solid Tumor predicted - sensitive Tanibirumab Phase I Actionable In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360). 28391576